Critical evaluation of molecular tumour board outcomes following 2 years of clinical practice in a Comprehensive Cancer Centre

URN to cite this document:: urn:nbn:de:bvb:355-epub-534982
DOI to cite this document:: 10.5283/epub.53498

Scheiter, Alexander

; Hierl, Frederik ; Lüke, Florian

; Keil, Felix

; Heudobler, Daniel

; Einhell, Sabine ; Klier-Richter, Margit ; Konstandin, Nikola P. ; Weber, Florian

; Scheiter, Andrea ; Kandulski, Arne ; Schlosser, Sophie

; Cosma, Lidia-Sabina ; Tews, Hauke ; Weiss, Andreas R. R.

; Grube, Matthias ; Bumes, Elisabeth

; Hau, Peter

; Proescholdt, Martin A.

; Steger, Felix ; Troeger, Anja ; Haferkamp, Sebastian

; Reibenspies, Lucas E. ; Schnabel, Marco J. ; Schulz, Christian

; Drexler, Konstantin ; Hatzipanagiotou, Maria E. ; Seitz, Stephan ; Klinkhammer-Schalke, Monika ; Unberath, Philipp ; Calvisi, Diego F.

; Pukrop, Tobias

; Dietmaier, Wolfgang ; Evert, Matthias ; Utpatel, Kirsten

License: Creative Commons Attribution 4.0
PDF - Published Version
(698kB)

Date of publication of this fulltext: 10 Jan 2023 07:41

Alternative links to fulltext:DOI Publisher

This publication is part of the DEAL contract with Springer.

Details

Preview

Export bibliographical data

Abstract

Recently, molecular tumour boards (MTBs) have been integrated into the clinical routine. Since their benefit remains debated, we assessed MTB outcomes in the Comprehensive Cancer Center Ostbayern (CCCO) from 2019 to 2021. Methods and results In total, 251 patients were included. Targeted sequencing was performed with PCR MSI-evaluation and immunohistochemistry for PD-L1, Her2, and mismatch ...